Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial

作者：Kwee Yong, T. John Martin, Meletios Α. Dimopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie‐Laure Risse, Philippe Moreau · 发表于：The Lancet Haematology · 年份：2024 · DOI：10.1016/s2352-3026(24)00148-0 · 被引用次数：23 · 研究领域：Multiple Myeloma Research and Treatments、Immunotherapy and Immune Responses、Cancer Mechanisms and Therapy